Introduction
============

In *Escherichia coli*, secretory proteins are targeted by means of the chaperone SecB and the ATPase SecA to the translocon of the plasma membrane, whose minimal pore consists of SecY, SecE, and SecG. In addition, *E*. *coli* contains Ffh (P48), which (together with 4.5S RNA) represents the bacterial homologue of the eukaryotic signal recognition particle (SRP), and FtsY, which is structurally related to the eukaryotic SRP receptor (SR) α subunit. Studies with conditional mutants of the SRP/SR components first suggested an involvement of the *E*. *coli* SRP and SR in the integration of proteins into the plasma membrane ([MacFarlane and Müller 1995](#N0x2a02840N0x2b3d870){ref-type="bib"}; [de Gier et al. 1996](#deGieretal1996){ref-type="bib"}; [Seluanov and Bibi 1997](#SeluanovandBibi1997){ref-type="bib"}; [Ulbrandt et al. 1997](#Ulbrandtetal1997){ref-type="bib"}). Recently, the first homologous assay system for SRP/SR of *E*. *coli* was described ([Koch et al. 1999](#Kochetal1999){ref-type="bib"}). Mannitol permease (MtlA) and SecY, two polytopic membrane proteins that lack large periplasmic domains, thus, were shown to require all three SRP/SR components for integration into inner membrane vesicles (INV) of *E*. *coli*. Most strikingly, integration of both proteins did not require SecA and SecB, whereas the translocation of a secretory protein (pOmpA) into INV was exclusively dependent on these Sec proteins. Both integration of MtlA and translocation of pOmpA, however, required an active SecY, suggesting that in *E*. *coli*, SRP/SR and SecA/SecB constitute two independent pathways that target specific substrates to the SecY-containing translocon of the plasma membrane. The specificity of SRP for polytopic inner membrane proteins is achieved by the ability of the ribosome-associated chaperone trigger factor to prevent binding of the SRP to the signal sequence of a secretory protein ([Beck et al. 2000](#Becketal2000){ref-type="bib"}).

The concept of an exclusively SRP-dependent integration of *E*. *coli* inner membrane proteins, however, is not consistent with recent reports demonstrating the involvement of SecA in the membrane assembly of FtsQ and of AcrB-PhoA fusions ([Valent et al. 1998](#Valentetal1998){ref-type="bib"}; [Qi and Bernstein 1999](#QiandBernstein1999){ref-type="bib"}). To obtain independent evidence that, in *E*. *coli*, SRP/SR are sufficient to mediate proper membrane integration of multispanning proteins harboring short periplasmic loops, we have now challenged the involvement in integration of those parts of the *E*. *coli* translocon that are known to mediate the SecA function (i.e., SecG and the COOH terminus of SecY).

Materials and Methods
=====================

Strains and Plasmids
--------------------

The following *E*. *coli* strains were used: MRE 600 ([Müller and Blobel 1984](#N0x2a02840N0x2b3d990){ref-type="bib"}), N4156 pARA14-FtsY′ ([Luirink et al. 1994](#Luirinketal1994){ref-type="bib"}), CJ107 (*secY24ts*) ([Wolfe et al. 1985](#Wolfeetal1985){ref-type="bib"}), TY0 (*ompT::kan*), TY1 (*ompT::kan*, s*ecY205*) ([Matsumoto et al. 1997](#Matsumotoetal1997){ref-type="bib"}), CU164 (*secY39*) ([Baba et al. 1990](#Babaetal1990){ref-type="bib"}), PS163 (*secEcs15*) ([Schatz et al. 1991](#Schatzetal1991){ref-type="bib"}), CM124 (*secE*Δ19-111, pCM22) ([Traxler and Murphy 1996](#TraxlerandMurphy1996){ref-type="bib"}), and KN553 ΔuncB-C::Tn10 ΔsecG::kan) ([Nishiyama et al. 1996](#Nishiyamaetal1996){ref-type="bib"}). For in vitro protein synthesis, the following plasmids were used: pDMB (OmpA) ([Behrmann et al. 1998](#Behrmannetal1998){ref-type="bib"}), p717MtlA-B (mannitol permease; [Beck et al. 2000](#Becketal2000){ref-type="bib"}), pJM8CS7 (SecY) ([Koch et al. 1999](#Kochetal1999){ref-type="bib"}), pLacY-Bla\#3 ([Prinz and Beckwith 1994](#PrinzandBeckwith1994){ref-type="bib"}), and p717LamB-B (λ receptor \[LamB\]). To create p717LamB-B, the 1.5-kb HindIII-EcoRI fragment of pLB8000 ([Swidersky et al. 1992](#Swiderskyetal1992){ref-type="bib"}) was truncated at the 5′ end and subcloned as a 1.4-kb BamHI-EcoRI fragment into pKSM717 ([Maneewannakul et al. 1994](#Maneewannakuletal1994){ref-type="bib"}). For in vitro expression of the *secY205* allele, the plasmid pJM8CS7 was mutagenized using the QuikChange Kit (Stratagene) and the mutagenic primers secY205-1 (5′-ATGTCCAGTCAGGATGAGTCTGCATTG-3′) and secY205-2 (5′-TACAGGTCAGTCCTACTCAGACGTAAC-3′). Thus, the plasmid pETSecY205 created carries a T to G point mutation within *secY* replacing Y429 with D. The presence of this mutation was confirmed by DNA sequencing.

In Vitro Reactions
------------------

In vitro protein synthesis and the preparation of its components was performed as previously described ([Hoffschulte et al. 1994](#Hoffschulteetal1994){ref-type="bib"}; [Koch et al. 1999](#Kochetal1999){ref-type="bib"}). INV of the temperature-sensitive *secY* mutant CJ107 were obtained from cells grown either at 30 or 42°C. For the preparation of INV from the *secE* mutant PS163, cells were incubated for 2 h at 37°C, and then shifted to 25°C for additional 4 h before harvesting. INV from strain CM124 were prepared from cells grown either in the presence or absence of arabinose. Urea treatment of INV (generating U-INV) was performed as previously described ([Helde et al. 1997](#Heldeetal1997){ref-type="bib"}).

SecY Integration Assay
----------------------

In vitro synthesis of wild-type SecY and SecY205 was performed in the presence of INV or U-INV prepared from the *secY205* mutant strain TY1. Mock-treated *secY205*-INV were generated by performing the in vitro reaction in the absence of DNA. When indicated, 8 ng/μl Ffh (P48) and 20 ng/μl FtsY were added. After 30 min incubation at 37°C, the entire reaction mixture was applied on a two-step sucrose gradient and separated into soluble material, membrane fraction, and pelleted material as described previously ([Koch et al. 1999](#Kochetal1999){ref-type="bib"}). The membranes were collected by centrifugation through a 750-mM sucrose cushion prepared in 50 mM triethanolamine acetate, pH 7.5, and employed for a translocation assay with in vitro synthesized OmpA as previously described ([Koch et al. 1999](#Kochetal1999){ref-type="bib"}). For U-INV, the translocation assay was performed in the presence of 80 ng/μl SecA, 80 ng/μl SecB, and 40 ng/μl F~1~-ATPase.

Sample Analysis and Quantification
----------------------------------

All samples were analyzed on 13% SDS--polyacrylamide gels. Radiolabeled proteins were visualized by phosphorimaging using a Molecular Dynamics PhosphorImager and quantified using ImageQuant software from Molecular Dynamics.

Results
=======

A secY Mutation Preventing a Productive Interaction with SecA Does Not Interfere with the Integration of Polytopic Membrane Proteins
------------------------------------------------------------------------------------------------------------------------------------

A number of *secY* mutants have been isolated that display a diminished capability to support translocation of secretory proteins and to stimulate the ATPase activity of SecA ([Baba et al. 1990](#Babaetal1990){ref-type="bib"}; [Matsumoto et al. 1997](#Matsumotoetal1997){ref-type="bib"}; [Taura et al. 1997](#Tauraetal1997){ref-type="bib"}). To analyze whether these mutants are equally defective in the integrase activity of SecY, we prepared inside-out inner membrane vesicles (INV) from the three *secY* mutants, *secY24ts*, *secY39cs*, *secY205cs*, and tested them for their ability to support the integration of MtlA. As shown in [Fig. 1](#F1){ref-type="fig"} a, INV from the *secY24ts* mutant cells, grown at the nonpermissive temperature (42°C), were significantly impaired in both translocation of pOmpA and integration of MtlA when compared with wild-type vesicles. Likewise, INV from the *sec39cs* mutant were defective in both translocation and integration activity, although the effect on integration was less severe than that on translocation when compared with the *secY24ts* mutant. In contrast, *secY205* INV, while possessing a strongly reduced translocation activity, did not exhibit any defect in the integration of MtlA.

Unimpaired integration into *secY205* INV was confirmed for two additional polytopic membrane proteins. Using a two-step sucrose gradient, we have recently shown that SecY itself, like MtlA, integrates into INV in a strictly SRP-dependent manner ([Koch et al. 1999](#Kochetal1999){ref-type="bib"}). As illustrated in [Fig. 1](#F1){ref-type="fig"} b, cosedimentation of SecY with the membranes (69% compared with 14% in the INV-free control) did not significantly change by using INV from the *secY205* mutant. Identical results were obtained with a LacY-Bla fusion protein, in which the first two transmembrane helices of lactose permease are fused to β-lactamase ([Prinz and Beckwith 1994](#PrinzandBeckwith1994){ref-type="bib"}). As for SecY, cosedimentation of LacY-Bla with INV occurs independently of SecA, but it requires both Ffh and FtsY (data not shown). Using the same sedimentation analysis, only a minor portion of OmpA could be recovered from the *secY205* membranes (data not shown). In summary, the *secY205* mutation, which specifically impairs the SecA--SecY interaction ([Matsumoto et al. 1997](#Matsumotoetal1997){ref-type="bib"}), does not interfere with the integration of the three membrane proteins tested here.

In Contrast to SecE, SecG Acting in Concert with SecA Is Not Required for the Integration of Polytopic Membrane Proteins
------------------------------------------------------------------------------------------------------------------------

There is substantial evidence that SecY, together with SecE and SecG, constitutes the central core of the membrane-embedded protein translocase for secretory proteins (for review see [Duong et al. 1997](#Duongetal1997){ref-type="bib"}). To test whether SRP-dependent membrane proteins also require SecE for integration, INV from two conditional *secE* mutants grown under permissive and nonpermissive conditions were prepared. As shown in [Fig. 2](#F2){ref-type="fig"} a, the integration of MtlA into INV obtained after depletion of SecE was impaired to the same drastic extent as the translocation of OmpA. A lack of SecE also interfered with the integration of SecY and LacY-Bla as demonstrated by cosedimentation analysis ([Fig. 2](#F2){ref-type="fig"} b, compare wild-type and *secE* INV). The diminished integration observed in these conditions was in fact due to a depletion of SecE. This was verified by Western blot analyses ([Fig. 2](#F2){ref-type="fig"} c), which also revealed, for both *secE* mutant vesicles, the previously reported destabilization of SecY in the absence of SecE ([Akiyama et al. 1996](#Akiyamaetal1996){ref-type="bib"}).

SecG, the third component of the translocase is involved in the translocation of secretory proteins by assisting the insertion of the SecA--preprotein complex into the translocation channel ([Nishiyama et al. 1994](#Nishiyamaetal1994){ref-type="bib"}, [Nishiyama et al. 1996](#Nishiyamaetal1996){ref-type="bib"}; [Matsumoto et al. 1997](#Matsumotoetal1997){ref-type="bib"}). Thus, it seemed conceivable that SecA-independent proteins do not require SecG for their membrane insertion. To examine this, INV were prepared from the *secG* mutant KN553 and tested for the integration of MtlA. As shown in [Fig. 2](#F2){ref-type="fig"} a, these INV did not exhibit any negative effect on MtlA integration, whereas translocation of OmpA was almost completely diminished. Strikingly, processing of pOmpA was not considerably altered in the *secG* mutant INV, albeit the obvious translocation defect. However, this effect was rather substrate specific since processing and translocation of pLamB, a second secretory protein tested, were both severely reduced by the same *secG* mutant INV ([Fig. 2](#F2){ref-type="fig"} d).

Membrane integration of SRP-dependent proteins in a SecG-independent manner was further substantiated for the two other membrane proteins SecY and LacY-Bla. Their cosedimentation with INV was not affected by the *secG* mutation, which clearly contrasts the results obtained with *secE* vesicles ([Fig. 2](#F2){ref-type="fig"} b). The finding that SecG is dispensable for the integration of membrane proteins is completely consistent with the observed SecA independence of this process.

SRP-dependent Integration of SecY into Membrane Vesicles Results in a Biologically Active Protein
-------------------------------------------------------------------------------------------------

The results described above rely on the premise that the integration of membrane proteins into INV, followed by the detection of protease resistance or cosedimentation with the vesicles, reflects the authentic in vivo events. The finding that the *secY205* mutation exclusively impairs the translocation of secretory proteins but not the integration of membrane proteins, enabled us to design an integration assay monitoring the biological activity of a membrane protein as a criterion for its correct assembly. The concept is that if in vitro synthesized wild-type SecY correctly inserts into INV derived from the *secY205* mutant, these INV would contain two versions of the SecY molecule, i.e., the inactive SecY205 version and the in vitro synthesized and integrated wild-type form. The latter should functionally reconstitute the mutant vesicles by restoring their translocation activity towards OmpA.

In a first step, SecY was synthesized in vitro in the presence of *secY205* INV as described in Material and Methods. These INV were used for a translocation assay with OmpA as a substrate. As shown above, *secY205* INV were not able to support translocation of OmpA ([Fig. 3](#F3){ref-type="fig"} a, lanes 5 and 6) in contrast to wild-type INV ([Fig. 3](#F3){ref-type="fig"}, lanes 3 and 4). However, if in vitro synthesized wild-type SecY had been allowed to integrate into *secY205* INV before the OmpA translocation assay, then the translocation efficiency increased almost 10-fold in comparison to mock-treated *secY205* INV ([Fig. 3](#F3){ref-type="fig"}, compare lanes 5 and 6 with 9 and 10). To confirm the ability of in vitro synthesized SecY to reconstitute *secY* mutant INV, despite being made in radiochemical amounts only, an inactive form of SecY was employed. When SecY205 instead of wild-type SecY was synthesized in vitro and allowed to integrate into mutant INV, the translocation activity of these vesicles did not increase beyond the level of mock-treated controls ([Fig. 3](#F3){ref-type="fig"}, compare lanes 5 and 6 with 7 and 8). The failure of in vitro synthesized SecY205 to reconstitute the mutant INV was, however, not due to reduced expression levels or impaired membrane association of the SecY205. As shown in [Fig. 1](#F1){ref-type="fig"} b, the SecY205 mutant protein was expressed in vitro and integrated into INV at a level indistinguishable from wild-type SecY.

We have previously shown that integration of membrane proteins into urea-treated INV (U-INV) is strictly dependent on exogenously added Ffh and FtsY ([Koch et al. 1999](#Kochetal1999){ref-type="bib"}). This finding was applied to the functional reconstitution of *secY205* INV with in vitro synthesized SecY. In contrast to untreated *secY205* INV, the OmpA translocation activity of *secY205* U-INV could not be restored by in vitro synthesized SecY alone ([Fig. 3](#F3){ref-type="fig"} b, compare lanes 9 and 10 with 11 and 12). However, if during reconstitution of *secY205* U-INV, Ffh and FtsY were provided, the reisolated vesicles exhibited a significantly increased translocation efficiency for OmpA (lanes 13 and 14). Restoration required SecY and was not due solely to the presence of Ffh and FtsY, neither during preincubation of the vesicles (lanes 7 and 8) nor during the translocation reaction (lanes 15 and 16). In summary, these results clearly demonstrate that in vitro synthesized SecY has acquired biological activity after its SRP-dependent integration into membrane vesicles.

Discussion
==========

Whether or not the integration of membrane proteins into the inner membrane of *E*. *coli* requires SecA in addition to SRP/SR, is still under debate. SecA can be cross-linked to nascent chains of the single spanning membrane protein FtsQ ([Valent et al. 1998](#Valentetal1998){ref-type="bib"}). Other membrane proteins that, like FtsQ, harbor long translocated domains were shown to depend on SecA for proper assembly ([Wolfe et al. 1985](#Wolfeetal1985){ref-type="bib"}; [Traxler and Murphy 1996](#TraxlerandMurphy1996){ref-type="bib"}; [Qi and Bernstein 1999](#QiandBernstein1999){ref-type="bib"}). On the other hand, two polytopic membrane proteins recently were found not to require SecA, but only SRP/SR for integration. In this in vitro analysis, the exclusively SRP-dependent integration of MtlA and SecY into INV was assessed by protease resistance and cosedimentation, respectively ([Koch et al. 1999](#Kochetal1999){ref-type="bib"}). We have now designed a functional assay for correct integration into INV, which is compatible with the low amounts of membrane proteins usually synthesized in vitro. The finding that in vitro synthesized SecY acquires its biological activity after being integrated into membrane vesicles is a clear indication that this SRP-dependent integration faithfully reproduces the in vivo events.

These functional studies in conjunction with a more recent analysis, probing the molecular environment of nascent secretory and membrane *E*. *coli* proteins by cross-linking ([Beck et al. 2000](#Becketal2000){ref-type="bib"}), altogether did not reveal any SecA dependence of the integration of multispanning membrane proteins devoid of major periplasmic loops. This is now further corroborated by two additional lines of evidence: (1) the integration of MtlA, LacY-Bla, and SecY is not affected by a mutation within the COOH-terminal domain of SecY that abolishes functional interaction with SecA. The theoretical possibility that SecA might still be involved in the integration of membrane proteins, yet in a manner not requiring interaction with the COOH terminus of SecY, is ruled out by the fact that the reconstitution of *secY205* vesicles with wild-type SecY does not require the addition of SecA. (2) SecG, whose topology inversion is tightly coupled to the membrane insertion of SecA ([Suzuki et al. 1998](#Suzukietal1998){ref-type="bib"}), is not required for the integration of MtlA, SecY, and LacY-Bla under conditions in which a lack of SecG almost completely abolishes the translocation of OmpA and LamB. Incidentally, the *secG* mutant INV had been prepared from an *E*. *coli* Δ*uncB-C* strain ([Nishiyama et al. 1996](#Nishiyamaetal1996){ref-type="bib"}) that lacks all components of the F~1~F~0~-ATPase. Under our experimental conditions, these vesicles cannot generate a H^+^ gradient. Nevertheless, integration of MtlA was unimpaired, which confirms earlier reports that the proton motive force is not required for the integration of such membrane proteins ([Ahrem et al. 1989](#Ahremetal1989){ref-type="bib"}; [Werner et al. 1992](#Werneretal1992){ref-type="bib"}).

The SecA/SecB- and SRP/SR-mediated targeting pathways converge at the SecYEG translocon, as evidenced by cross-linking studies ([Valent et al. 1998](#Valentetal1998){ref-type="bib"}; [Beck et al. 2000](#Becketal2000){ref-type="bib"}). This has been confirmed by the use of translocation intermediates that block the SecYEG channel and equally inhibit the translocation of OmpA as well as the integration MtlA ([Koch et al. 1999](#Kochetal1999){ref-type="bib"}). In addition, depletion of SecE not only affects the translocation of secretory proteins, but also the integration of membrane proteins ([Schatz et al. 1991](#Schatzetal1991){ref-type="bib"}; [Traxler and Murphy 1996](#TraxlerandMurphy1996){ref-type="bib"}; [de Gier et al. 1998](#deGieretal1998){ref-type="bib"}; and this study). In SecE-depleted membranes, SecY is rapidly degraded by the FtsH protease ([Akiyama et al. 1996](#Akiyamaetal1996){ref-type="bib"}). The cytoplasmic domain C4 of SecY seems to be important for the SecY--SecE interaction since the *secY24ts* mutation positioned in the C4 domain of SecY abolishes copurification of SecE and SecY ([Baba et al. 1994](#Babaetal1994){ref-type="bib"}; [Homma et al. 1997](#Hommaetal1997){ref-type="bib"}). Therefore, it is conceivable that the defects of the *secY24ts* mutant in both translocation and integration are primarily the result of an impaired SecY--SecE interaction. Interestingly, whereas the translocation defect of *secY24* INV is partially suppressed by the addition of SecA ([Fandl et al. 1988](#Fandletal1988){ref-type="bib"}), no such improvement was observed for the integrase function of *secY24ts* INV (our unpublished results) which lends further support to the SecA independence of this process. Thus, in addition to SecE, the C4 domain of SecY might also interact with SecA.

Mutations within the C5 and C6 cytoplasmic domains of SecY interfere with the translocase activity of SecY ([Baba et al. 1990](#Babaetal1990){ref-type="bib"}; [Taura et al. 1997](#Tauraetal1997){ref-type="bib"}). We show here that the *secY39cs* mutation, located within domain C5, also negatively affects the integration activity of SecY, yet to a lesser degree than translocation. On the other hand, the *secY40* mutation, which is located in close proximity to the *secY39* mutation selectively impairs the integration of fusions between membrane proteins and alkaline phosphatase, but has only minor effects on the translocation of secretory proteins ([Newitt and Bernstein 1998](#NewittandBernstein1998){ref-type="bib"}). The *secY205* mutant, which carries a mutation at the very COOH terminus of SecY, is specifically defective in the ATP-dependent SecA insertion into the plasma membrane ([Matsumoto et al. 1997](#Matsumotoetal1997){ref-type="bib"}). This defect causes a significant translocation deficiency for SecA-dependent proteins ([Taura et al. 1997](#Tauraetal1997){ref-type="bib"}; and this study), but leaves the integration of membrane proteins like MtlA, LacY-Bla, or SecY unaffected. In conclusion, while the SecY translocon is used for translocation of secretory proteins across, and integration of membrane proteins into the plasma membrane of *E*. *coli*, both activities can be dissected because they depend on different domains of SecY and require different components of the translocon.
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![The *secY205* mutant is exclusively impaired in the translocation of secretory proteins but not in the integration of polytopic membrane proteins. (a) The polytopic membrane protein mannitol permease (MtlA) and the secretory protein OmpA were synthesized in vitro in a cell-free translation system in the presence of inside-out inner membrane vesicles (INV) that were prepared from wild-type and different *secY* mutant strains. \[^35^S\]methionine-labeled translation products were either directly precipitated with TCA or only after incubation with 0.5 mg/ml proteinase K (PK) for 20 min at 25°C. Indicated are the positions of full-length MtlA, the membrane-protected fragment of MtlA resistant toward proteinase K (MtlA-MPF), the precursor (pOmpA), and the signal sequence--free form of OmpA. The percentage of integration was calculated after quantification of the radioactivity of individual protein bands using a PhosphorImager and calculating the ratio between MtlA-MPF and MtlA. The values obtained were corrected for the loss of Met residues occurring during cleavage by proteinase K. The percentage of translocation equals the ratio of radioactivity present in the proteinase K--resistant bands of pOmpA and OmpA and that recovered from the corresponding bands before proteolytic digestion. The values shown represent the means of at least three independent experiments with the SDs given in parenthesis. (b) Three polytopic inner membrane proteins, SecY, SecY205, a mutated version of SecY, and a lactose permease fusion protein (LacY-Bla) were synthesized in vitro in the presence of wild-type or *secY205* INV. Membrane association was analyzed by subfractionation of the reaction mixture on a two-step sucrose gradient. Three fractions were sequentially withdrawn and analyzed on SDS-PAGE: the supernatant (sup), the membrane fraction (mem), and the pellet fraction (pel). Radioactivity present in the individual bands was quantified, and the sum of the three subfractions was each set at 100%.](JCB9910089.f1){#F1}

###### 

In contrast to SecE, SecG is not required for the integration of polytopic membrane proteins. (a) MtlA and OmpA were synthesized in vitro as detailed in [Fig. 1](#F1){ref-type="fig"} in the presence of inner membrane vesicles prepared either from the wild-type, the cold-sensitive *secE* mutant PS163, the SecE-depletion mutant CM124, or the *secG* mutant KN553. Integration and translocation were quantified as described in [Fig. 1](#F1){ref-type="fig"}. (b) Integration of SecY and LacY-Bla into INV, derived from the *secG* KN533 mutant, or the *secE* mutant CM124, grown in the absence of arabinose, was analyzed as specified in [Fig. 1](#F1){ref-type="fig"}. (c) Immunoblot of wild-type and *secE* mutant vesicles using rabbit antisera directed against SecY and SecE and an HRP-based enhanced chemiluminescence detection system. (d) Translocation of pLamB was analyzed as specified for pOmpA translocation in [Fig. 1](#F1){ref-type="fig"}.
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###### 

SecY synthesized in vitro and integrated into INV is biologically active. (a) To reconstitute the *secY205* INV in a first step, wild-type SecY and, as a negative control, SecY205 were in vitro synthesized in the presence of *secY205* INV (pretreatment). The *secY205* INV were isolated and subsequently tested for their ability to support the translocation of in vitro synthesized OmpA. No pretreatment was performed in the control reactions shown in lanes 1--4. Translocation was quantified as specified in [Fig. 1](#F1){ref-type="fig"}. (b) To demonstrate the SRP dependency of the reconstitution process, vesicles were extracted with urea (U-INV) to remove Ffh and FtsY before reconstitution with in vitro synthesized SecY. Readdition of Ffh (SRP) and FtsY (SR) is indicated. After the individual pretreatments, vesicles were isolated and subsequently tested for translocation activity towards OmpA.
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